Cargando…

The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure

INTRODUCTION: The present study was intended to investigate the effect of levosimendan on high-sensitivity C-reactive protein (hsCRP) levels in hospitalized patients with decompensated heart failure. MATERIAL AND METHODS: The present study was designed as a prospective controlled clinical trial. A t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korkmaz, Hasan, Yilmaz, Mücahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705148/ https://www.ncbi.nlm.nih.gov/pubmed/31448350 http://dx.doi.org/10.5114/amsad.2019.86803

Ejemplares similares

Association of Mitral Annulus Calcification with High-Sensitivity C-Reactive Protein, Which Is a Marker of Inflammation
por: Kurtoğlu, Ertuğrul, et al.
Publicado: (2012)

Newer treatments for decompensated heart failure: focus on levosimendan
por: Follath, Ferenc
Publicado: (2009)

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010)

Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study
por: Çavuşoğlu, Yüksel, et al.
Publicado: (2016)

Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
por: Juguet, William, et al.
Publicado: (2020)

Levosimendan improves hemodynamic effects in patients with acutely decompensated heart failure: the Argentinean multicenter registry
por: Perrone, SV, et al.
Publicado: (2003)

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure
por: Suominen, Pertti K
Publicado: (2011)

Levosimendan use in the emergency management of decompensated peripartum cardiomyopathy
por: Uriarte-Rodríguez, Alina, et al.
Publicado: (2010)

Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies
por: Pereira-Barretto, AC, et al.
Publicado: (2003)

High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients
por: Ferreira, João Pedro, et al.
Publicado: (2014)

Use of levosimendan in acute heart failure
por: Harjola, Veli-Pekka, et al.
Publicado: (2018)

Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure
por: Mebazaa, A, et al.
Publicado: (2004)

Efficiency and Safety of Prolonged Levosimendan Infusion in Patients with Acute Heart Failure
por: Aidonidis, Georgios, et al.
Publicado: (2011)

Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered
por: Sanfilippo, Filippo, et al.
Publicado: (2021)

The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure
por: Michalopoulou, H, et al.
Publicado: (2007)

Could neutrophil/lymphocyte ratio be an indicator of coronary artery disease, coronary artery ectasia and coronary slow flow?
por: Yılmaz, Mücahid, et al.
Publicado: (2016)

Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
por: Qu, Chao, et al.
Publicado: (2022)

Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients
por: Zhang, Dengqing, et al.
Publicado: (2015)

Intermittent levosimendan infusions in advanced heart failure: a real world experience
por: Ortis, Benedetta, et al.
Publicado: (2017)

Use of Levosimendan in Patients with Advanced Heart Failure: An Update
por: Masarone, Daniele, et al.
Publicado: (2022)

Levosimendan benefits critically ill patients with decompensated heart failure assessed with plasma B-type natriuretic peptide (BNP) and LVEF
por: McLean, AS, et al.
Publicado: (2003)

Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
por: John, Basil, et al.
Publicado: (2021)

Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure
por: Lee, Wei-Chieh, et al.
Publicado: (2022)

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis
por: Jaguszewski, Milosz J., et al.
Publicado: (2021)

A review of levosimendan in the treatment of heart failure
por: Kasikcioglu, Hulya Akhan, et al.
Publicado: (2006)

Levosimendan in pulmonary hypertension and right heart failure
por: Hansen, Mona Sahlholdt, et al.
Publicado: (2018)

Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
por: Garratt, C, et al.
Publicado: (2004)

Relationship between B-type natriuretic peptide plasma levels and echocardiography parameters in decompensated chronic heart failure patients treated with levosimendan
por: Ferri, MB, et al.
Publicado: (2006)

Decompensated heart failure
por: Mangini, Sandrigo, et al.
Publicado: (2013)

Predictors of low cardiac output in decompensated severe heart failure
por: Ochiai, Marcelo Eidi, et al.
Publicado: (2011)

Acute Kidney Disease After Acute Decompensated Heart Failure
por: Chen, Jia-Jin, et al.
Publicado: (2022)

Prognostic value of fibrosis-5 index combined with C-reactive protein in patients with acute decompensated heart failure
por: Wang, Ziyan, et al.
Publicado: (2023)

Association of Repetitive Dosing of Levosimendan with Reduction of NYHA Class and NT-proBNP Levels in Decompensated Heart Failure: A Retrospective Cohort Study
por: Wechsler, Maximilian, et al.
Publicado: (2022)

Repetitive levosimendan treatment in the management of advanced heart failure
por: Oliva, Fabrizio, et al.
Publicado: (2018)

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction
por: DuBrock, Hilary M., et al.
Publicado: (2018)

Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap
por: Conti, Nicolina, et al.
Publicado: (2021)

Association of colchicine use for acute gout with clinical outcomes in acute decompensated heart failure
por: Roth, Mary E., et al.
Publicado: (2022)

Prospective Study on the Postoperative Use of Levosimendan After Conventional Heart Valve Replacement
por: Sheng, Wei, et al.
Publicado: (2021)

C-reactive protein at discharge and 1-year mortality in hospitalised patients with acute decompensated heart failure: an observational study
por: Nishimoto, Yuji, et al.
Publicado: (2020)

Iatrogenic Decompensated Heart Failure
por: Tran, Patrick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqj011q7qkue3sjaep763rtklo